Article

The new gas permeable contact lenses

High and hyper Dk values provide us with the opportunity to use larger lens designs, which are especially helpful for post-graft patients or those with large cones or pellucid marginal degeneration.

Key Points

If your patient is primarily interested in crisp, clear vision, then he or she will be delighted with GP lenses. Historically, the drawback with GP lenses has been comfort. Today, GP lenses never have been more comfortable, and the comfort level is only expected to keep getting better. Contact lens manufacturers are on a mission to improve oxygen transmissibility and wetting angles. In fact, since 1998, the FDA has approved high Dk lenses for extended wear up to 7 days.

The first use of GP lenses overnight was for orthokeratology, also called Ortho-K. Although many eye-care professionals thought that consumers would flock to optical dispensaries to be fitted with this alternative to refractive surgery, growth has been slow. In fact, in 1998, 16% of the contact lens-wearing population was using GP products. According to the Contact Lens Council, in 2000, the number of GP users declined to 15% of the overall 34 million contact lens wearers. That small decline in GP usage should not be taken as a sign of their demise, but rather as the motivation for current technological advancements.












If you tried fitting a multifocal GP lens more than 5 years ago and were not impressed, the latest designs make it well worth another try. Eye-care professionals now can choose from a variety of lens designs-simultaneous or alternating (also called translating), aspheric or spherical-and the lenses can correct up to 2.75 D add power.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.